Prince Pharmaceutical Co., Ltd.

As of June 30, 2026, Prince Pharmaceutical Co., Ltd. carries a market capitalization of 1.11B, placing it among publicly traded companies globally. Its enterprise value stands at 1.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Prince Pharmaceutical Co., Ltd. has 37.77M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Prince Pharmaceutical Co., Ltd. maintains a current ratio of 1.69, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Prince Pharmaceutical Co., Ltd.'s stock has declined approximately 11.73% over the past 52 weeks. The 50-day moving average sits at 28.76, while the 200-day moving average is 29.32.

As of June 30, 2026, Prince Pharmaceutical Co., Ltd. holds 224.85M in cash and equivalents against 408.28M in total debt, resulting in a net debt position of 55.95M. Total book value stands at 871.54M, with working capital of 283.15M providing operational flexibility.

Prince Pharmaceutical Co., Ltd.'s most recent stock split took place on August 20, 2026 with a 518:523 split ratio.